



Ausgerichtete Forschungsbeiträge ab 2012

Nr.	Gesuchsteller	Titel Gesuch	bewilligter Betrag	Dauer
144	Herr Oliver GAUTSCHI, PD Dr. med.	SAKK 19/09 Bevacizumab, pemetrexed and cisplatin, or erlotinib and bevacizumab for advanced non-squamous NSCLC stratified by EGFR mutation status. A multicenter phase II trial including biopsy at progression (BIO-PRO trial)	59'000.--	24 Mte
145	Herr Urban NOVAK, Dr. med.	Whole-exome sequencing of aggressive mediastinal lymphomas in two female siblings	75'000.--	18 Mte
146	Herr Julian SCHARDT, M.D., Ph.D.	Investigating the combined cytotoxic effect of the Cox-2 inhibitor Celecoxib and the proteasome inhibitor Bortezomib in leukemic cells	30'000.--	6 Mte
147	Frau Anja Maria SCHMITT KURRER, Dr. med.	The role of angiogenesis and hypoxia signaling in the response prediction to targeted therapy of pancreatic neuroendocrine tumors pNET	76'000.--	24 Mte
148	Frau Eva DIAMANTIS, MD	Role of MicroRNAs and PTEN/PI3K/AKT pathway in pancreatic cancer progression from localized to metastatic disease. Relationship to tumor budding, prognosis and response to adjuvant therapy	70'000.--	24 Mte
149	Herr Thomas PABST, Prof. Dr. med.	Randomized evaluation of vinorelbine versus gemcitabine for mobilization of peripheral stem cells in myeloma patients undergoing autologous stem cell transplantation	50'000.--	24 Mte
150	Herr Mauricio REYES, PhD	Medical Image Analysis for Brain Tumor Studies	30'000.--	24 Mte
151	Frau Leslie SAURER, PhD	Significance of Triggerin Receptor expressed on myeloid cells-1 (8TERM-1) in experimental colorectal cancer (CRC) development and its role as prognostic marker in human CRC	45'000.--	12 Mte
152	Herr Stephan VON GUNTEN, PD Dr. med.	Siglec-7 and Siglec-9 receptors on NK cells: expression and function in cancer	55'000.--	12 Mte
153	Herr Jean-François DUFOUR, Prof. Dr. med.	The Bern HCC cohort	20'000.--	24 Mte
154	Frau Sabine HÖPNER, Dr.	Lymphotoxin-beta receptor (LTβR) signaling in leukemic stem cells	40'000.--	24 Mte
155	Herr Thomas MARTI, Dr. phil. nat.	Targeting tumor initiating cells in lung cancer	60'000.--	36 Mte
156	Frau Loretta MÜLLER, PhD	Carcinogenic Potential of Gasoline Car Exhaust (including Nanoparticles) and their Effect on Natural Killer Cells	45'000.--	36 Mte
157	Herr Christoph SCHLAPBACH, MD, PhD	Characterizing human interleukin 9-producing T helper memory cells and their role in antitumor immune response in malignant melanoma	50'000.--	12 Mte
158	Herr Philippe SCHUCHT, Dr. med.	Extent of resection thresholds as predictor of survival in patients with glioblastoma	25'000.--	48 Mte



159	Frau Audrey BOUCHET, PhD	Increased vascular permeability by synchrotron microbeam radiation generates a highly efficient drug delivery system for tumor treatment	60'000.--	24 Mte
160	Herr Ren-Wang PENG, PhD	Functional identification and molecular targeting of human lung cancer stem cells	70'000.--	36 Mte
161	Herr Stephan SCHÄFER, MD	Molecular characterisation of adenosquamous carcinoma of the lung as a prime type model of tumourheterogeneity	70'000.--	18 Mte
162	Frau Sabina BEREZOWSKA, Dr. med.	Resistance mechanisms to ALK inhibitors in EML4-ALK positive non-small cell lung cancer (NSCLC) - the role of autophagy	32'000.--	12 Mte
163	Frau Vanessa BANZ, Dr.	Targeting YAP for the treatment of hepatocellular carcinoma using verteporfin and VisudyneTM: a promising new strategy	100 000.00	18 Mte
164	Frau Viktoria GLOY, Dr. sc.	Preventing and reducing adverse events in radioiodine therapy of thyroid cancer: A systematic review and meta-analysis	45 000.00	18 Mte
165	Herr Sean HALL, Dr. phil. nat.	Role of PD-L1-expressing pericyte-like cells in non-small cell lung cancer	60 000.00	12 Mte
166	Herr Reng-Wang PENG, PhD	Functional identification and molecular targeting of human lung cancer stem cells	105 000.00	18 Mte
167	Frau Lena SOKOL, Dr.	cDNA library for (mi)RNA detection in distinct cell populations of archived FFPE colorectal cancer tissue	60 000.00	12 Mte
168	Frau Michaela MEDOVA, PhD	Impact of PI3K mutations on MET receptor tyrosine kinase targeting in head and neck cancer	60 000.00	18 Mte
169	Herr Ruslan HLUSHCHUK, Dr	Novel microangioCT contrast agent enables 3D visualization and quantitative evaluation of the tumor vasculature down to the capillary level with the	60 000.00	24 Mte
170	Herr Bastian DISLICH, Dr. med. PhD	The role of autophagy for resistance to Her2 directed therapy in adenocarcinomas of the upper gastrointestinal tract	60 000.00	12 Mte
171	Herr Alan DAL PRA, Dr.	PROMET: Multicenter, Randomized, Double Blind, Placebo Controlled Phase II Trial of Salvage Radiotherapy+/- Metformin HCL after Prostatectomy Failure	70 000.00	18 Mte
172	Herr Julian SCHARDT, M.D., Ph.D.	Identification of genetic alterations in circulating tumor cells associated with the development of resistance to targeted therapies in kidney cancer	60 000.00	18 Mte
173	Frau Anna SCHLÄFLI, Dr. phil. nat.	Improving retinoic acid therapy in breast cancer by autophagy modulation	80 000.00	18 Mte
174	Herr Benedikt WEBER, Dr. med.	Correlation of different Vascular Endothelial Growth Factor (VEGF) subtypes and their respective receptors (VEGFRs) with malignant melanoma disease	40 000.00	18 Mte
175	Herr Nicolas BONADIES, Dr. med.	Biological Characterization of Clonal Dynamics and Converging Oncogenic Pathways in Refractory/Relapsing High-risk Myelodysplastic Syndromes	80 000.00	18 Mte
176	Herr Steffen EYCHMÜLLER, Prof. Dr. med.	Best Care of the Dying Person during the Last Days of Life: A Qualitative Study about Patient-Defined and Proxy-Defined Core Outcomes	30 000.00	18 Mte
177	Herr Peiling LUAN, MSc	Characterization and therapeutic targeting of chemoresistance-driving pathways in lung cancer	120 000.00	18 Mte
178	Herr Mathias WORNİ, MD MHS	electroporation lead to a prolonged and potent t-cell mediated immune response compared to surgical resection?	70 000.00	18 Mte
179	Herr Mathias DETTMER, PD Dr.	Tumor heterogeneity and epigenetics in high-risk thyroid carcinomas	70 000.00	18 Mte
180	Herr Marc FURRER, pract.med.	wie wirken sich verschiedene patientenspezifische, anästhesiologische und operationstechnische Parameter auf Komplikationen sowie funktionelle und onkologische Endpunkte nach radikaler Zystektomie aus?	40 000.00	18 Mte



181	Herr Radau OLARIU, Dr. med.	Transcutaneous sentinel lymph node identification in malignant melanoma using Indocyanine Green. A prospective diagnostic accuracy clinical trial.	20 000.00	18 Mte
182	Herr Andrea PAPADIA, M.D., PhD	Redirecting the natural history of HPV infection through immune checkpoint inhibitors	25 000.00	18 Mte
183	Frau Grit SOMMER, Dr. rer. nat.	Pulmonary late-effects in long-term childhood cancer survivors - Development of guidelines for follow-up care	25 000.00	18 Mte
184	Frau Kathrin ZAUGG, PD Dr.	Cutting edge radiation therapy: Effect of delivery time and dose rate on tumour cell survival and invasion and its clinical impact	70 000.00	12 Mte
185	Frau Yara BANZ, PD Dr.	The role of interleukin-33/ST2 signaling in the pathogenesis of malignant lymphoma	65 000.00	18 Mte
186	Herr Patrick DORN, Dr. med.	Targeting mitochondrial activity to enhance lung cancer therapy	90 000.00	18 Mte
187	Frau Magali HUMBERT, PhD	Understanding the role of Macro- and Chaperone-Mediated Autophagy in Leukemia Development and Sustainment	85 000.00	18 Mte
188	Frau Sara IMBODEN, Dr. med.	Moving towards personalized medicine in endometrial cancer: classification of endometrial cancer according to TCGA subgroups - a clinic orientated, multicentre	10 000.00	6 Mte
189	Herr Gregor KOCHER, PD Dr. med.	Identify therapeutic targets to promote chemotherapy efficacy in KRAS-mutant lung cancer by CRISPR screen	80 000.00	18 Mte
190	Herr Christian FERNANDEZ PALOMO, PhD	Combining Microbeam Synchrotron Radiotherapy & Gold-nanoparticles: A Novel anti-cancer approach to treat melanoma	70 000.00	18 Mte
	TOTAL		2 420 000.00	